



PATENT ELIGIBILITY RESTORATION ACT (PERA)

PERA Would Clarify Patent Eligibility to Promote U.S. Innovation and Competitiveness

Clear, consistent rules about what inventions are patent eligible allow inventors, venture capitalists, and other stakeholders to confidently invest in the research and development needed to invent new technologies and power the U.S. innovation economy. However, more than a decade of court decisions have muddled the waters and made it more difficult to obtain patents for inventions in critical technology areas, including artificial intelligence (AI), biotechnology, and personalized medicine.

The judicially created restrictions on patent eligibility puts the United States at a competitive disadvantage as foreign governments seize on opportunities to expand the scope of eligible subject matter in their countries. As a result, there are many inventions that are patentable in China and Europe but rejected as ineligible in the United States.

The Patent Eligibility Restoration Act (PERA) (S.2140) — a bipartisan bill introduced by Senate Judiciary IP Subcommittee Chair Chris Coons (D-DE) and Ranking Member Thom Tillis (R-NC) — would eliminate the confusion created by courts as to what inventions are patent eligible and help regain the U.S. competitive edge in innovation.

Legislation Is Needed To Clarify Supreme Court Patent Eligibility Precedent

- Section 101 of the Patent Act (35 U.S.C. § 101) defines the categories of inventions that are eligible to receive patents.
- In a series of decisions beginning in 2010, the Supreme Court established a new test for patent eligibility and significantly expanded existing judicially created exceptions to patent eligibility for abstract ideas, mathematical formulas, and products of nature.[1]
- Under the new test, a court must determine whether an invention is “directed to” one of the ineligible categories, and, if so, whether the claim contains an additional “inventive concept.” Both of these determinations involve highly subjective decisions for which the Supreme Court has provided no further guidance. The “inventive concept” analysis also requires courts to consider novelty and non-obviousness, muddying the waters between Section 101 and distinct Section 102 and 103 statutory requirements for patentability.
- Collectively, these decisions have all but eliminated inventors’ ability to obtain patents for inventions in key sectors—including computer software, AI, and life sciences—and made patent rights less predictable across almost all technologies.
- Lower courts, the Solicitor General, USPTO directors, and other stakeholders have all acknowledged that the Supreme Court’s test for patentability leads to inconsistent and unpredictable results. The Supreme Court has also declined to provide more guidance and certainty by rejecting review of more than 100 cases on these issues. This has led to calls for Congress to pass legislation to clarify patent subject-matter eligibility.

PERA Clarifies Patent Subject-Matter Eligibility

- PERA resolves confusion by retaining Section 101's existing statutory categories for patent-eligible subject matter (i.e., process, machine, manufacture, and composition of matter) and by replacing the ambiguous judicially created exceptions with more clearly defined exceptions.
 - PERA lists specific exceptions to eligible subject matter and ensures that they will be the only exceptions. These exceptions include pure mathematical formulas, certain economic or social processes, processes that can be performed solely in the human mind, processes that can occur in nature independent of human activity, unmodified human genes, and unmodified natural material.
 - PERA also clarifies the narrow conditions under which otherwise unpatentable processes, genes, and materials may be eligible for a patent, subject to other statutory requirements (e.g., novelty and non-obviousness). For example, under PERA, a process that cannot be practically performed without the use of a machine or computer may be eligible for a patent. The bill also clarifies that human genes and natural materials that are "isolated, purified, enriched, or otherwise altered by human activity" or "employed in a useful invention or discovery" may be eligible for a patent.
-

PERA Restores Clear Test for Patent Eligibility Determinations

- Under current law, patent examiners and courts determining whether a claimed invention is eligible for a patent under Section 101 must consider vague factors, including whether portions of a claim include elements that are "conventional" or "routine."
- These considerations blur the line between Section 101 and other statutory requirements for a patent, such as novelty and non-obviousness under Sections 102 and 103.
- PERA requires a patent claim to be read as a whole and prohibits the consideration of other patentability factors (e.g., novelty and non-obviousness), ensuring Section 101 focuses solely on subject-matter eligibility.

[1] *Bilski v. Kappos*, 561 U.S. 593 (2010) (under which most patents on business methods are now ineligible); *Mayo Collaborative Services v. Prometheus Laboratories*, 566 U.S. 66 (2012) (under which most diagnostic testing patents are now ineligible); *Association for Molecular Pathology v. Myriad Genetics, Inc.*, 569 U.S. 576 (2013) (under which gene-fragment patents are ineligible); *Alice Corp. v. CLS Bank International*, 573 U.S. 208 (2014) (under which most software patents are ineligible).